share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

SEC announcement ·  Aug 2 05:51
Summary by Futu AI
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.